SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-20-024744
Filing Date
2020-05-12
Accepted
2020-05-12 17:31:48
Documents
53
Period of Report
2020-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q tptx-10q_20200331.htm 10-Q 1799495
2 EX-31.1 tptx-ex311_6.htm EX-31.1 19368
3 EX-31.2 tptx-ex312_9.htm EX-31.2 19322
4 EX-32.1 tptx-ex321_7.htm EX-32.1 10162
5 EX-32.2 tptx-ex322_8.htm EX-32.2 10173
  Complete submission text file 0001564590-20-024744.txt   5236270

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT tptx-20200331.xml EX-101.INS 1041741
7 XBRL TAXONOMY EXTENSION SCHEMA tptx-20200331.xsd EX-101.SCH 32988
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE tptx-20200331_cal.xml EX-101.CAL 37743
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE tptx-20200331_def.xml EX-101.DEF 83491
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE tptx-20200331_lab.xml EX-101.LAB 280934
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tptx-20200331_pre.xml EX-101.PRE 207712
Mailing Address 10628 SCIENCE CENTER DRIVE, SUITE 200 SAN DIEGO CA 92121
Business Address 10628 SCIENCE CENTER DRIVE, SUITE 200 SAN DIEGO CA 92121 858-926-5251
Turning Point Therapeutics, Inc. (Filer) CIK: 0001595893 (see all company filings)

IRS No.: 463826166 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38871 | Film No.: 20870284
SIC: 2834 Pharmaceutical Preparations